All In Biotech

Drug Trial Radar · NCT05238922

Study of INCB123667 in Subjects With Advanced Solid Tumors

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

291

Actual

Start

Jul 5, 2022

Primary completion

Jul 27, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Feb 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).

Conditions

  • Solid Tumors

Interventions

  • INCB0123667Drug

    25 mg tablets

  • PalbociclibDrug

    Palbociclib will be administered at protocol defined dose.

  • BevacizumabDrug

    Bevacizumab will be administered at protocol defined dose.

  • OlaparibDrug

    Olaparib will be administered at protocol defined dose.

  • PaclitaxelDrug

    Paclitaxel will be administered at protocol defined dose.

  • RibociclibDrug

    Ribociclib will be administered at protocol defined dose.

  • FulvestrantDrug

    Fulvestrant will be administered at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to Day 28
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 12 months
  3. Number of Participants with Dose Interruptions due to TEAETime frame: Up to 12 months
  4. Number of Participants who Undergo Dose Reductions due to TEAETime frame: Up to 12 months
  5. Number of Participants Discontinue study due to TEAETime frame: Up to 12 months

Locations

41 sites in 8 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

  • City of Hope-Lennar Foundation Cancer Center

    Irvine, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Rocky Mountain Cancer Centers-Sky Ridge

    Lone Tree, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Mount Sinai Medical Center Comprehensive Cancer Center

    Miami Beach, Florida

  • Emory University

    Atlanta, Georgia

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • New York Presbyterian/Weill Cornell

    New York, New York

  • Ny Cancer and Blood Specialists

    Shirley, New York

  • Carolina Bio-Oncology Institute, Pllc

    Huntersville, North Carolina

  • University of Pennsylvania Abramson Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Cancer Institute Cancer Services

    Pittsburgh, Pennsylvania

  • Allegheny Health Network

    Pittsburgh, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology-Fort Worth South Henderson

    Fort Worth, Texas

  • Virginia Cancer Institute

    Fairfax, Virginia

  • University of Wisconsin

    Madison, Wisconsin

  • Institut Bergonie

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, Italy

  • Istituto Nazionale Tumori Irccs Fondazione Pascale

    Naples, Italy

  • Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore

    Rome, Italy

  • Irccs Istituto Clinico Humanitas

    Rozzano, Italy

  • Centro Ricerche Cliniche Di Verona

    Verona, Italy

  • Aichi Cancer Center Hospital

    Aichi, Japan

  • National Cancer Center Hospital East

    Chiba-ken, Japan

  • Saitama Medical University International Medical Center

    Hidaka-shi, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • The Cancer Institute Hospital of Jfcr

    Tokyo, Japan

  • Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • Panoncology Trials Pan American Center For Oncology Trials, Llc

    Rio Piedras, Puerto Rico

  • Oncological Institute of Southern Switzerland

    Bellinzona, Switzerland

  • Inselspital Universitatsklinik Fur Medizinische Onkologie

    Bern, Switzerland

  • Centre Hospitalier Universitaire Vaudois (Chuv)

    Lausanne, Switzerland

  • Guys Hospital

    London, United Kingdom

  • Imperial College Healthcare Nhs Trust - Hammersmith Hospital

    London, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.